ResearchIn-Press PreviewCell biologyNeuroscience
Open Access |
10.1172/jci.insight.192155
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Wolfe, S. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Ma, Y. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Yaron-Barir, T. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Chang, C. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Pilo, C. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Ghassemian, M. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by
Roberts, A.
in:
PubMed
|
Google Scholar
|
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Lee, S. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Henson, B. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Jepsen, K. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by
Johnson, J.
in:
PubMed
|
Google Scholar
|
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Cantley, L. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Taylor, S. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Gorrie, G. in: PubMed | Google Scholar
1Department of Pharmacology, University of California, San Diego, La Jolla, United States of America
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
3Department of Chemistry and Biochemistry, Biomolecular and Proteomics Mass Spectrometry Facility, University of California, San Diego, La Jolla, United States of America
4Animal Models Core Facility, The Scripps Research Institute, La Jolla, United States of America
5The UCSD Transgenic Mouse Core, University of California, San Diego, La Jolla, United States of America
6Institute for Genomic Medicine, University of California, San Diego, La Jolla, United States of America
7Queen Elizabeth University Hospital, Glasgow, United Kingdom
Find articles by Newton, A. in: PubMed | Google Scholar
Published April 2, 2026 - More info
Spinocerebellar Ataxia Type 14 (SCA14) is an autosomal dominant neurodegenerative disease caused by mutations in the gene encoding protein kinase C gamma (PKCγ), a Ca2+/diacylglycerol (DG)-dependent serine/threonine kinase dominantly expressed in cerebellar Purkinje cells. These mutations impair autoinhibitory constraints to increase the basal activity of the kinase, resulting in deficits in the cerebellum that are not observed upon simple deletion of the gene, and severe ataxia. To better understand the impact of aberrant PKCγ signaling in disease pathology, we developed a knock-in murine model of the SCA14 mutation ΔF48 in PKCγ. This fully-penetrant mutation is severe in humans and is mechanistically informative as it has high basal activity but is unresponsive to agonist stimulation. Genetic, behavioral, and molecular testing revealed that ΔF48 PKCγ mice have ataxia-related phenotypes and an altered cerebellar phosphoproteome driven primarily by enhanced Ca2+/calmodulin-dependent Kinase II (CaMKII) signaling, effects that were more severe in male mice. Analysis of existing human data revealed that SCA14 has a significantly earlier age of onset for males compared with females. Data from this clinically relevant mutation suggested that enhanced basal activity of PKCγ is sufficient to cause ataxia and that treatment strategies to modulate aberrant PKCγ may be particularly beneficial in males.